SCHEMBL1496367

SCHEMBL1496367

O=C(Nc1ccc(O)cc1)c1cccnc1SCc1ccnc2ccccc12

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 4/20 0.53
KMT2A Q03164 2/20 0.47
ALDH1A1 P00352 2/20 0.46
GAA P10253 2/20 0.46
DEGS1 O15121 1/20 0.45
FLT1 P17948 2/20 0.44
NR4A1 P22736 1/20 0.44
ESR2 Q92731 1/20 0.44
ACLY P53396 1/20 0.43
LMNA P02545 2/20 0.43
MEN1 O00255 1/20 0.43
DNMT1 P26358 1/20 0.43
DNMT3L Q9UJW3 1/20 0.43
DNMT3A Q9Y6K1 1/20 0.43
PABPC1 P11940 1/20 0.42
EIF4H Q15056 1/20 0.42
CYP2C9 P11712 1/20 0.42
NSD2 O96028 1/20 0.41
PKM P14618 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1496280 0.92 KDR (0.53) KDRKMT2AALDH1A1GAAFLT1
SCHEMBL1496366 0.91 KDR (0.66) KDRKMT2AALDH1A1GAAFLT1
SCHEMBL1496305 0.89 KDR (0.50) KDRKMT2AALDH1A1GAAFLT1
SCHEMBL1496364 0.88 HTR2C (0.53) KDRKMT2AALDH1A1GAAFLT1
SCHEMBL1496360 0.88 KDR (0.57) KDRKMT2AALDH1A1GAAFLT1
SCHEMBL1496413 0.88 KDR (0.42) KDRKMT2AALDH1A1GAAFLT1
SCHEMBL1496273 0.86 KDR (0.48) KDRKMT2AALDH1A1GAANR4A1
SCHEMBL1496334 0.86 KDR (0.56) KDRKMT2ALMNAMEN1L3MBTL1
SCHEMBL1496313 0.86 KDM4E (0.45) KDRKMT2AALDH1A1GAANR4A1
SCHEMBL1347000 0.85 ALDH1A1 (0.47) KDRKMT2AALDH1A1GAALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1854787-B1 NOVEL CYCLIC COMPOUND HAVING QUINOLYLALKYLTHIO GROUP SANTEN PHARMACEUTICAL CO LTD (JP) 2010-09-01 EP claimed
US-20080021064-A1 Novel cyclic compound having quinolylalkylthio group SANTEN PHARMACEUTICAL CO., LTD. (JP) 2008-01-24 US claimed
EP-1854787-A1 NOVEL CYCLIC COMPOUND HAVING QUINOLYLALKYLTHIO GROUP SANTEN PHARMACEUTICAL CO., LTD. (JP) 2007-11-14 EP claimed
US-7897774-B2 Cyclic compound having quinolylalkylthio group SANTEN PHARMACEUTICAL CO., LTD. (JP) 2011-03-01 US disclosed
EP-1854787-B1 NOVEL CYCLIC COMPOUND HAVING QUINOLYLALKYLTHIO GROUP SANTEN PHARMACEUTICAL CO LTD (JP) 2010-09-01 EP disclosed
US-20080021064-A1 Novel cyclic compound having quinolylalkylthio group SANTEN PHARMACEUTICAL CO., LTD. (JP) 2008-01-24 US disclosed
EP-1854787-A1 NOVEL CYCLIC COMPOUND HAVING QUINOLYLALKYLTHIO GROUP SANTEN PHARMACEUTICAL CO., LTD. (JP) 2007-11-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080021064-A1 Novel cyclic compound having quinolylalkylthio group SQOR, QSOX1, SQLE KDR 3463/4885KMT2A 2435/4885ALDH1A1 1108/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.